Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 10/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2374370 | 0.90 | APP (0.45) | APP | |
| SCHEMBL2375255 | 0.90 | APP (0.45) | APP | |
| SCHEMBL2373666 | 0.89 | APP (0.37) | APPLMNAESR1CYP1A2CYP2D6 | |
| SCHEMBL2374407 | 0.82 | APP (0.62) | APP | |
| SCHEMBL2374401 | 0.82 | APP (0.62) | APP | |
| SCHEMBL2373672 | 0.78 | APP (0.42) | APPLMNATSHRMAPK1CYP2C19 | |
| SCHEMBL2374622 | 0.78 | APP (0.42) | APP | |
| SCHEMBL2373975 | 0.78 | APP (0.64) | APP | |
| SCHEMBL2386945 | 0.78 | APP (0.64) | APP | |
| SCHEMBL2374372 | 0.71 | APP (0.65) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363392-B1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | UNIV PENNSYLVANIA (US) | 2017-05-03 | — | — | EP | disclosed |
| US-8840866-B2 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-09-23 | — | — | US | disclosed |
| US-8506929-B2 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130129624-A1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-05-23 | — | — | US | disclosed |
| EP-1999109-B1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | UNIV PENNSYLVANIA (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2363391-A1 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | The Trustees of The University of Pennsylvania (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2363392-A1 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | The Trustees of The University of Pennsylvania (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7687052-B2 | radiolabeling; neurodegenerative diseases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090123369-A1 | Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1999109-A2 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | The Trustees Of The University Of Pennsylvania (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20080038195-A1 | radiolabeling; neurodegenerative diseases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2007126733-A2 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130129624-A1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | APP, APBA1, PSEN1 | APP 1/4885RARB 4706/4885LMNA 1760/4885 |
| US-20080038195-A1 | radiolabeling; neurodegenerative diseases | APP, PSEN1, HTT | APP 1/4885RARB 4807/4885LMNA 2384/4885 |
| US-20090123369-A1 | Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques | APP, APBA1, PSEN1 | APP 1/4885RARB 4706/4885LMNA 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.